INTRINSIC: A Multi-Arm Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer
Condition: Colon or Rectal Cancer
Sponsor: Hoffmann-La Roche
Full Title
WO42758: A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer
Study Treatment
Arm C: Anti-TIGIT immunotherapy tiragolumab + atezolizumab +/- bevacizumab
Eligibility/Info
Arm C: Patients with a stage IV colon or rectal adenocarcinoma that is MSI-high and that has previously been treated with at least 1 anti-cancer treatment regimen that included an immunotherapeutic agent.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
